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We combined in a previously derived three-dimen-
sional model of the histamine H1 receptor (Ter Laak,
A. M., Timmerman, H., Leurs, H., Nederkoorn, P. H. J.,
Smit, M. J., and Donne-Op den Kelder, G. M. (1995)
J. Comp. Aid. Mol. Design. 9, 319–330) a pharmacophore
for the H1 antagonist binding site (Ter Laak, A. M., Ven-
horst, J., Timmerman, H., and Donne´-Op de Kelder, G. M.
(1994) J. Med. Chem. 38, 3351–3360) with the known in-
teracting amino acid residue Asp116 (in transmembrane
domain III) of the H1 receptor and verified the predicted
receptor-ligand interactions by site-directed mutagene-
sis. This resulted in the identification of the aromatic
amino acids Trp167, Phe433, and Phe436 in transmem-
brane domains IV and VI of the H1 receptor as probable
interaction points for the trans-aromatic ring of the H1
antagonists. Subsequently, a specific interaction of car-
boxylate moieties of two therapeutically important,
zwitterionic H1 antagonists with Lys
200 in transmem-
brane domain V was predicted. A Lys2003 Ala mutation
results in a 50- (acrivastine) to 8-fold (d-cetirizine) loss
of affinity of these zwitterionic antagonists. In contrast,
the affinities of structural analogs of acrivastine and
cetirizine lacking the carboxylate group, triprolidine
and meclozine, respectively, are unaffected by the
Lys2003 Ala mutation. These data strongly suggest that
Lys200, unique for the H1 receptor, acts as a specific
anchor point for these “second generation” H1
antagonists.
Since the initial discovery of the role of histamine in allergic
conditions (1) serious efforts have been made to develop drugs
that inhibit the actions of histamine. Already in 1933, Four-
neau and Bovet (2) reported the first “antihistamine” piper-
oxan. Following this finding many potent H1 antagonists that
can be considered as variations of diaryl-substituted ethyl-
amines (e.g. diphenhydramine and mepyramine) have been
developed (for review see Ref. 3). These “first generation” H1
antagonists are quite effective in humans in allergic rhinitis
and urticaria, but because of central nervous system penetra-
tion and central H1 receptor blockade their clinical use is ham-
pered by sedative side effects (3–5). A “second generation” of
nonsedative H1 antagonists (e.g. astemizole, acrivastine, ceti-
rizine, loratidine, and terfenadine) has recently been developed
(for review see Ref. 3). Their altered pharmacokinetics result in
good clinical effectiveness combined with a strongly reduced
sedative potential (3–5).
The development of H1 antagonists has so far been directed
by traditional medicinal chemistry (3). With the availability of
the genetic information of the histamine H1 receptor (6), the
rationalization of drug-protein interaction has become a major
challenge for this therapeutically important class of drugs.
Like all aminergic G-protein coupled receptors (GPCR),1 the H1
receptor contains an aspartate residue (Asp116) in transmem-
brane domain (TM) III (6), that is involved in the binding of the
protonated amine function found in both agonists and antago-
nists structures (7, 8). Mutagenesis studies have furthermore
shown that the imidazole ring of histamine is accommodated by
Lys200 and Asn207 in TM V (9, 10).
In view of the low sequence similarity between GPCRs and
bacteriorhodopsin (BR) much controversy exists on the validity
of models derived for GPCRs based on the homology with BR
(11–13). Nevertheless, despite the speculative nature of BR-
derived GPCR models they have been quite helpful in under-
standing and predicting drug-receptor interactions for a vari-
ety of receptors (see e.g. Refs. 14–16). Previously, we also
developed a three-dimensional computer model of the hista-
mine H1 receptor based on the homology with BR, incorporat-
ing the results obtained from mutagenesis studies on the ago-
nist binding site (17). In the present study this computer model
of the H1 receptor was combined with a pharmacophoric model
of the H1 antagonistic binding site (18). This ligand-based
model for the H1 antagonistic binding site is based upon an
interaction of the protonated amine function of various first
generation, semi-rigid H1 antagonists with an aspartate resi-
due (Asp116 in the guinea pig H1 receptor) (18) and precisely
positions the cis- and trans-aromatic rings of the H1 antago-
nists relative to the Ca and Cb carbon atoms of this aspartate
residue. Combining the three-dimensional receptor model and
the ligand-based pharmacophoric model of the H1 antagonist
binding site resulted in the prediction of interactions of aro-
matic amino acids in TM IV and VI with the H1 antagonists.
Subsequently, we experimentally confirmed the involvement of
these predicted amino acids in the binding of the H1 antagonist
[3H]mepyramine by site-directed mutagenesis. Moreover, on
the basis of the three-dimensional model of the antagonist-
receptor complex, a specific interaction of carboxylate moieties
of therapeutically important, second generation zwitterionic H1
antagonists (acrivastine and cetirizine) with Lys200 in TM V
was predicted and experimentally verified.* The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
“advertisement” in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
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EXPERIMENTAL PROCEDURES
Materials—Bovine serum albumin, DEAE-dextran, polyethylenei-
mine, and triprolidine hydrochloride were obtained from Sigma. The
mouse anti-FLAG M2 monoclonal antibody was obtained from Interna-
tional Biotechnology Inc. The fluorescein isothiocyanate-conjugated
rabbit-anti-mouse secondary antibody was supplied by Dakopatts AB
(Stockholm, Sweden). [3H]Mepyramine (28 Ci/mmol) was obtained from
Amersham Pharmacia Biotech. Gifts of acrivastine (The Wellcome
Foundation Ltd., London, United Kingdom), d-cetirizine hydrochloride,
meclozine hydrochloride (UCB, Braine-l’Alleud, Belgium), and mian-
serin hydrochloride (Organon NV, Oss, the Netherlands) are gratefully
acknowledged.
Predicition of Ligand-Receptor Interactions—H1 antagonists were
docked in the previously described three-dimensional receptor model of
the guinea pig H1 receptor (17), using the rigid H1 antagonist pharma-
cophoric model of Ter Laak et al. (18). This model describes the three-
dimensional topology of the cis- and trans-aromatic rings of cyprohep-
tadine with respect to the positions of the Ca and Cb carbon atoms of an
putative Asp residue from the receptor (see Fig. 1A). The Ca and Cb
carbon atoms of the pharmacophore replaced the corresponding atoms
of Asp116 in the receptor model. Rotation was carried out along the
Ca-Cb bond until cyproheptadine was positioned in the receptor in an
energetically favorable orientation. The structure of the zwitterionic
compounds acrivastine and d-cetirizine were built and optimized with
Chem-X and subsequently docked into the H1 receptor model onto the
cyproheptadine template as described previously (18). Subsequently, all
freely rotatable bonds in Lys200 and in the side chains of the zwitteri-
onic H1 antagonist were taken into account in an extensive conforma-
tional analysis (MacroModel/AMBER force field (19)).
Site-directed Mutagenesis—The guinea pig H1 receptor cDNA was
subcloned in the pALTER vector (Promega), and point mutations were
introduced according to the manufacturer’s protocol. The wild type and
mutant receptors were epitope-tagged with an N-terminal FLAG pep-
tide (DYKDDDD) after modification of the cDNA sequence with polym-
erase chain reaction. In our initial binding studies (see Fig. 2) non-
tagged receptors were used. The cDNA sequences were verified using
the dideoxy chain termination method with the Sequenase kit (U. S.
Biochemical Corp.).
Cell Culture and Transfection—COS-7 and HEK-293 cells were
grown at 37 °C in a humidified atmosphere with 5% CO2 in Dulbecco’s
modified Eagle’s medium, containing 2 mM L-glutamine, 50 IU/ml pen-
icillin, 50 mg/ml streptomycin, and 5 or 10% (v/v) fetal calf serum,
respectively. Cells were transiently transfected with pcDNA3, contain-
ing the wild type or mutant H1 receptor cDNA, using DEAE-dextran
(COS-7 cells) or calcium phosphate (HEK-293 cells).
Histamine H1 Receptor Binding Studies—Transfected cells were har-
vested after 48 h, homogenized in ice-cold 50 mM Na2/potassium phos-
phate buffer (pH 7.4) and used for radioligand binding studies. Cell
homogenates (40–50 mg of protein) were incubated for 30 min at 25 °C
in 50 mM Na2/potassium phosphate buffer (pH 7.4) in 400 ml with the
indicated concentrations of [3H]mepyramine. The nonspecific binding
was defined in the presence of 1 mM mianserin. In displacement studies,
cell homogenates were incubated with 1 nM [3H]mepyramine and in-
creasing concentrations of competing ligands. The incubations were
stopped by rapid dilution with 3 ml of ice-cold 50 mM Na2/potassium
phosphate buffer (pH 7.4). The bound radioactivity was separated by
filtration through Whatman GF/C filters that had been treated with
0.3% polyethyleneimine. Filters were washed twice with 3 ml of buffer,
and radioactivity retained on the filters was measured by liquid scin-
tillation counting. The binding data were evaluated by a nonlinear,
least squares curve fitting procedure. Protein levels were determined
according to Bradford (20), using bovine serum albumin as standard.
[3H]Inositol Phosphate Production—HEK-293 cells were seeded in
12-well plates and 24 h after transfection labeled overnight in inositol-
free culture medium supplemented with 2 mCi/ml myo-[2-3H]inositol.
Cells were stimulated for 1 h at 37 °C with Dulbecco’s modified Eagle’s
medium containing 25 mM Hepes (pH 7.4), 20 mM LiCl, and histamine.
The incubation was stopped by aspiration of the culture medium
and the addition of cold CHCl3/methanol (1:2 v/v). After extraction
with water, [3H]inositol phosphates were isolated by anion exchange
chromatography (21).
Immunofluorescence—Transfected COS-7 cells were grown on glass
coverslips and after 48 h fixed with 4% paraformaldehyde/phosphate-
buffered saline for 30 min at room temperature and blocked in phos-
phate-buffered saline/0.1% bovine serum albumin for 1 h at room tem-
perature. Antigen detection was performed as described (22).
RESULTS
Prediction of Ligand-Receptor Interaction Based on Receptor
Modelling—The H1 antagonist pharmacophoric model of Ter
Laak et al. (18) represents low energy conformations of several
potent and rigid H1 antagonists (cyproheptadine, phenindam-
ine, triprolidine, epinastine, mequitazine, and mianserine) and
is able to discriminate between the stereochemically different
cis- and trans-aromatic rings of these H1 antagonists (Fig. 1A).
To predict amino acid residues involved in the ligand-binding
site of these H1 antagonists the cyproheptadine pharmaco-
phore was docked into the previously derived model of the H1
FIG. 1. A, the H1 antagonist pharmacophore of Ter Laak et al. (18) describing the position of the cis- and trans-aromatic rings of H1 antagonists
with respect to the Ca and Cb carbon atoms of a putative aspartate residue. B, the H1 antagonist pharmacophore was docked into the H1 receptor
model based on BR (17). A view from the extracellular side shows the orientation of cyproheptadine between the TMs (yellow) and the ionic
hydrogen bond interaction with Asp116 in TM III. The trans-aromatic ring of cyproheptadine is in the proximity of Phe433, Phe 436 (TM VI), and
Trp167 (TM IV), and the cis-aromatic ring is near Trp161 (TM IV). Two other aromatic residues that were mutated in this study (Phe435 and Trp174)
are not in the proximity of the H1 antagonist in this model. Phe
435 points toward the membrane, and Trp174 is not shown because in this alignment
the residue lies outside the TM region.
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receptor. After rotation over the Ca-Cb bond of Asp
116 and
energy optimizations, a single energetically favorable orienta-
tion was found for the H1 antagonist. In this orientation the
aromatic rings of the H1 antagonist were located in the recep-
tor-binding pocket between the TMs III, IV, V, and VI (Fig. 1B).
The aromatic rings of cyproheptadine were surrounded by sev-
eral aromatic amino acids. In the H1 receptor model, the cis-
ring of cyproheptadine is located within 5 Å of a tryptophane in
TM IV (Trp161), whereas the trans-aromatic ring is close to two
phenylalanines in TM VI (Phe433 and Phe436) and Trp167 in TM
IV (Fig. 1B). All these predicted residues are conserved in all
the reported H1 receptor sequences (23–29).
Verification of the H1 Antagonist-binding Site by Site-di-
rected Mutagenesis—To verify the interaction of H1 antagonists
with the predicted amino acids these residues were initially
mutated to alanines. Moreover, two related amino acids (Trp174
in TM IV and Phe435 in TM VI) that are also conserved in all
the reported H1 receptor sequences (23–29) but not predicted
by the GPCR model were also mutated. In the derived model
Phe435 points into the phospholipid bilayer (Fig. 1B), and
Trp174 is located just outside TM IV.
The mutant receptors were expressed transiently in COS-7
cells and analyzed by [3H]mepyramine saturation binding
studies. Expression of the wild type H1 receptor in COS-7 cells
resulted in a high affinity binding site for [3H]mepyramine (KD
5 0.7 6 0.1 nM, mean 6 S.E., n 5 3) (Fig. 2). Mutation of the
tryptophane residues Trp161, Trp167, and Trp174 in TM IV to
alanine residues resulted in distinct effects on the [3H]mepyra-
mine binding to the mutant receptors (Fig. 2). The introduction
of the Trp174 3 Ala mutation did not reduce the affinity of
[3H]mepyramine (Fig. 2; KD 5 3.6 6 0.6 nM, mean 6 S.E., n 5
3) dramatically. In contrast, for the Trp167Ala receptor the
affinity for the H1 antagonist was reduced more than 10-fold
(Fig. 2; KD . 15 nM, n 5 3), whereas cells expressing the Trp
161
3 Ala receptor did not show binding of [3H]mepyramine (Fig.
2) significantly higher than binding to mock-transfected COS-7
cells (15–50 fmol/mg protein; data not shown). Similar findings
were obtained with the three Phe-Ala mutations in TM VI. The
Phe435Ala receptor mutant still bound [3H]mepyramine with
high affinity (Fig. 2; KD 5 1.3 6 0.2 nM, mean 6 S.E., n 5 3),
whereas for the other two mutants a reduced (Phe436 3 Ala
receptor, KD . 15 nM, n 5 3) or totally impaired (Phe
4333 Ala
receptor) [3H]mepyramine binding was observed (Fig. 2).
To verify protein expression of the two receptor mutants that
did not show detectable [3H]mepyramine binding (Trp1613 Ala
and Phe433 3 Ala), a FLAG epitope was introduced at the N
terminus of the wild type and mutant H1 receptor proteins.
Using confocal laser microscopy we identified specific, anti-
FLAG immunofluorescence in the plasma membrane of COS-7
cells expressing the epitope-tagged wild type and the Phe4333
Ala H1 receptor (Fig. 3). For the Trp
1613 Ala H1 receptor, the
anti-FLAG immunofluorescence was mainly found inside the
cell, indicating perturbed receptor expression.
Based on the observed loss of antagonist affinity upon mu-
tation of Trp167, Phe433, and Phe436, we considered these amino
acids as likely candidates for the hypothezised interaction with
the aromatic rings of the H1 antagonist. To investigate the role
of Trp161, Trp167, Phe433, and Phe436 in more detail, we changed
the tryptophane residues in TM IV to methionine and phenyl-
alanine (Trp161 3 Met, Trp161 3 Phe, Trp167 3 Met, and
Trp167 3 Phe) and the phenylalanine residues in TM 6 to
methionine (Phe433 3 Met and Phe436 3 Met). The mutant
receptors were epitope-tagged, expressed in COS-7 cells, and
evaluated for [3H]mepyramine binding. In contrast to the
Trp1613 Ala receptor mutant, the Trp1613Met and Trp1613
Phe receptor mutants bound [3H]mepyramine with high affin-
ity (Table I). Yet the number of binding sites for the Trp161 3
Phe receptor mutant was considerably lower compared with
the wild type and the Trp1613 Met receptor mutant (Table I).
As found for the Trp167 3 Ala receptor mutant, mutation of
Trp167 to Met or Phe resulted in strongly reduced affinity for
[3H]mepyramine (Table I). In contrast, mutating Phe433 and
Phe436 to Met allowed [3H]mepyramine binding with high af-
finity (Table I).
The affinity of the Trp161 3 Met and Trp161 3 Phe mutant
receptors for histamine was not changed (Table I), whereas a
small to major reduction of the agonist affinity was observed for
the Phe433 3 Met and Phe436 3 Met receptor mutants (Table
I). Because of the lack of saturable [3H]mepyramine binding,
the agonist affinity could not be determined for the other
mutants.
Histamine-induced [3H]Inositol Phosphate Accumulation af-
ter Stimulation of Wild Type and Mutant H1 Receptors—To test
the functionality of the mutant receptors, we initially per-
formed [3H]inositol phosphate accumulation experiments in
transfected COS-7 cells. However, in mock-transfected COS-7
cells histamine increased basal [3H]inositol phosphate accumu-
lation, suggesting the presence of an endogenously expressed
H1 receptor.
2 In mock-transfected HEK-293 cells histamine did
not stimulate the [3H]inositol phosphate accumulation (Fig. 4),
whereas after overexpression of the epitope-tagged wild type
H1 receptor protein (7.1 6 1.0 pmol/mg protein, mean 6 S.E.,
n 5 3) histamine (100 mM) stimulated the [3H]inositol phos-
phate accumulation 5.9 6 0.4-fold (mean 6 S.E., n 5 3) over
basal levels (Fig. 4). Evaluation of the various receptor mutants
showed that the Trp161 3 Met, Phe433 3 Ala, Phe433 3 Met,
Phe4363 Ala, and Phe4363 Met mutant receptors stimulated
the [3H]inositol phosphate accumulation as the wild type H1
receptor (Fig. 4). Similar EC50 values for histamine were ob-
served for the wild type receptor and the Trp1613Met, Trp161
3 Phe, and Phe4333 Ala receptors, whereas the Phe4333Met,
Phe436 3 Ala, and Phe436 3 Met mutant receptors were stim-
ulated less effectively by histamine (Table I). The expression
levels of the mutant receptors in HEK-293 cells ranged from 2.4
(Phe4363 Ala) to 10.6 pmol/mg protein (Trp1613Met). For the
Phe433 3 Ala mutant no radioligand binding was found. As
expected by the perturbed membrane expression, the Trp1613
Ala receptor mutant did not respond to histamine (Fig. 4). As
found for the expression in COS-7 cells, the Trp161 3 Phe was
expressed at relatively low levels in HEK-293 cells (0.3 6 0.1
2 K. Wieland, H. Timmerman, and R. Leurs, unpublished
observations.
FIG. 2. Effects of the mutation of aromatic amino acids in TM
IV and VI on the binding of the H1 antagonist [
3H]mepyramine
to wild type, Phe435 3 Ala, Trp174 3 Ala, Trp167 3 Ala, Phe436 3
Ala, Trp161 3 Ala, and Phe433 3 Ala H1 receptor after transient
expression in COS-7 cells. The data shown are from a representative
example out of at least three independent experiments.
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pmol/mg protein, means 6 S.E., n 5 3). Despite its low expres-
sion level a significant stimulation (Fig. 4) of the mutant re-
ceptor by histamine was observed with comparable potency as
the wild type receptor (Table I). For the various mutations of
Trp167 only the Trp167 3 Phe mutation resulted in a mutant
receptor that could be activated by histamine, although with a
very low efficacy (Fig. 4 and Table I). Because of the lack of
saturable binding in the [3H]mepyramine binding studies, the
expression levels of these mutant receptors could not be
estimated.
Predicted Interaction of the Zwitterionic H1 Antagonists Ac-
rivastine and Cetirizine with Lys200—To investigate whether
the acidic moiety of the nonsedative, zwitterionic H1 antagonist
acrivastine specifically interacts with the H1 receptor protein,
this ligand was docked into the H1 receptor model on top of the
template cyproheptadine. Visual inspection of the resulting
ligand-receptor complex suggested a possible interaction with
Lys200 in TM V. Following this observation a conformational
analysis, giving rotational freedom to Lys200 and the carboxy-
late group of the H1 antagonist, indeed predicted an interaction
between the positively charged Lys200 and the carboxylate
group (Fig. 5A). In the case of d-cetirizine, the carboxylate
group is attached to the basic nitrogen via a long ether chain.
Docking cetirizine in the H1 receptor model indicated that the
carboxylate of d-cetirizine reaches the proximity of Lys200, al-
though the calculated N-O distance of 3.57 Å is somewhat large
for a strong (ionic) hydrogen bond interaction (Fig. 5B).
Interaction of H1 Antagonists with Lys
200 in TM V—To verify
the predicted interaction of Lys200 with the carboxylate group
of acrivastine, we mutated the basic lysine to alanine and
methionine to disrupt the potential ionic interaction with the
H1 antagonist. We also mutated Lys
200 to an arginine residue,
because this basic amino acid should be able to interact with
the carboxylate group of acrivastine. Previously, we showed
that Lys200 in TM V specifically interacts with some classes of
H1 agonists (including histamine) but not with the prototypic
H1 antagonists [
3H]mepyramine and d- and l-chlorphenira-
mine (10). Moreover, also the Lys200 3 Arg and the Lys200 3
Met mutations allowed high affinity [3H]mepyramine binding
after expression in COS-7 cells and similar to the Lys2003 Ala
mutant (10) showed a slightly altered affinity for histamine
(Table II). Functional studies in HEK-293 cells indicated that
cells transiently transfected with the mutant receptors all re-
sponded to histamine with the accumulation of [3H]inositol
phosphates, although the EC50 values were higher than found
for the wild type receptor (Table II). Displacement of the bind-
ing of [3H]mepyramine to the Lys2003 Ala, Lys2003 Arg, and
Lys2003Met receptor mutants indicated a specific interaction
FIG. 3. Localization of epitope-tagged wild type (WT) and mutant H1 receptors, transiently expressed in COS-7 cells. Transfected
COS-7 cells were grown on glass coverslips and after 48 h fixed with 4% paraformaldehyde. Immunofluorescence was detected with the mouse
anti-FLAG M2 antibody and a fluorescein isothiocyanate-conjugated secondary rabbit anti-mouse antibody.
TABLE I
Effects of point mutations in TM 1V and V1 of the histamine H1 receptor on ligand binding and signal transduction
Receptors were expressed in COS-7 cells or HEK-293 cells and used 48 h after transfection for radioligand binding studies and the accumulation
of [3H]inositol phosphates, respectively. Data were calculated as the means 6 S.E. from at least three independent experiments. ND indicates that
the value was not determined.
Receptor KD [
3H]mepyramine H1 receptor density Ki histamine EC50 histamine Basal stimulation
nM pmol/mg protein mM mM fold
Wild type 0.7 6 0.1 9.5 6 1.2 76 6 19 0.04 6 0.02 5.9 6 0.4
Trp161 3 Ala 0a ND ND 0.9 6 0.1
Trp161 3 Met 1.6 6 0.2 18.6 6 1.8 124 6 8 0.08 6 0.06 6.5 6 0.5
Trp161 3 Phe 1.6 6 0.1 1.6 6 0.2 70 6 6 0.07 6 0.02 1.5 6 0.1
Trp167 3 Ala .15 ND ND ND 1.2 6 0.3
Trp167 3 Met .15 ND ND ND 1.5 6 0.2
Trp167 3 Phe .15 ND ND 217 6 138 3.0 6 0.2
Trp174 3 Ala 3.6 6 0.6 1.1 6 0.4 ND ND ND
Phe433 3 Ala 0b ND 0.06 6 0.02 6.0 6 0.8
Phe433 3 Met 5.4 6 0.4 17.2 6 0.2 208 6 13 0.4 6 0.1 5.6 6 0.1
Phe435 3 Ala 1.3 6 0.2 0.9 6 0.3 ND ND ND
Phe436 3 Ala .15 ND ND 210 6 136 4.7 6 0.5
Phe436 3 Met 3.5 6 0.3 12.8 6 4.9 33 6 36 6.3 6 2.2 6.8 6 1.0
a Positive anti-FLAG immunofluorescence signals only inside the cell.
b Positive anti-FLAG immunofluorescence signals in the membrane.
FIG. 4. Basal (open bars) and histamine (100 mM) (closed bars)
induced production of [3H]inositol phosphates by wild type and
mutant H1 receptors expressed in [
3H]inositol prelabeled HEK-
293 cells. The data shown are the means 6 S.E. of at least three
independent experiments.
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of Lys200 with acrivastine. The Ki value for acrivastine was
increased more than 50-fold following the Lys200 3 Ala and
Lys200 3 Met mutations (Fig. 6A and Table II). In contrast,
acrivastine still showed high affinity for the Lys200 3 Arg
receptor mutant (Fig. 6A and Table II). To further substantiate
these findings we tested the affinity of triprolidine, a structural
analog of acrivastine lacking the carboxylate moiety (Table III),
for the Lys2003 Ala receptor mutant. As expected, the affinity
of this close structural analog was not reduced by the Lys2003
Ala mutation (Fig. 6B and Table III). The Lys200 residue is also
involved in a specific interaction with the nonsedative, zwitte-
rionic H1 antagonist d-cetirizine (Fig. 6C and Table III). Again,
no effect of the Lys2003 Ala mutation was found on the affinity
of the analog meclozine, which does not contain a functional
group that can interact with the Lys200 residue in TM V (Fig.
6C and Table III).
DISCUSSION
More than 25 years after the initial hypothesis of Nauta et al.
(30) of an interaction of the trans-aromatic ring of the H1
antagonist diphenhydramine with a Phe residue of an hypo-
thetical a-helical structure of the H1 receptor, we identified the
aromatic amino acids Trp167, Phe433, and Phe436 in the puta-
tive a-helical TMs IV and VI of the H1 receptor as probable
interaction points for the trans-aromatic ring of the H1 antag-
onists. Moreover, we found Lys200 (TM V) to be a specific
anchor point for the carboxylate moiety of the nonsedative,
zwitterionic second generation H1 antagonists acrivastine and
cetirizine.
The basis for the identification of these amino acids came
from the docking of an H1 antagonistic pharmacophoric model
(18) into a previously derived three-dimensional model of the
H1 receptor (17). As a representative example of the first gen-
eration H1 antagonists, the rigid tricyclic cyproheptadine was
allowed to interact with its protonated amine function with the
highly conserved Asp116 in TM III (7, 8). Several aromatic
amino acid residues were predicted to interact with the aro-
matic rings of the H1 antagonist. Mutation of Trp
174 and
Phe435, which were predicted to not be involved in ligand bind-
ing, had indeed no effect on the [3H]mepyramine binding. In
contrast, for the mutant Trp1673 Ala and Phe4363 Ala recep-
tors a dramatic loss of affinity of [3H]mepyramine was ob-
served. Moreover, the Phe433 3 Ala mutation caused a total
loss of H1 antagonist binding, despite membrane expression of
the receptor protein and normal responsiveness toward hista-
mine. Replacing Phe433 and Phe436 with the hydrophobic but
aliphatic Met residue only slightly affected the binding of
[3H]mepyramine, indicating that these two Phe residues in
TMVI are most likely involved in a hydrophobic interaction
with the H1 antagonist. Furthermore, a large reduction in the
affinity and efficacy of histamine was observed for the Phe436
mutants. This observation fits well with our recently developed
model for the agonist interaction with the H1 receptor. In this
model an interaction of Phe436 with the imidazole ring of his-
tamine is predicted.3 Also for the Phe433 3 Met mutant lower
affinity and efficacy are observed. In our model for the agonist-
receptor interaction, a direct involvement of Phe433 with the
agonist binding is not predicted,3 as substantiated by the full
agonist activity at the Phe433 3 Ala mutant. Currently, we
cannot explain the reduced agonist responses at the Phe433 3
Met mutant, although we can speculate that the flexible Met
side chain prevents optimal agonist-receptor interaction by
steric hindrance.
Replacing Trp167 with either the aromatic Phe or the ali-
phatic hydrophobic Met did not allow high affinity [3H]mepyra-
mine binding. Yet, the Trp1673 Phe receptor mutant was able
to functionally interact with histamine. These data suggest
that Trp167 is important for high affinity [3H]mepyramine
binding but that hydrophobicity or aromaticity per se is not
sufficient for a proper interaction. This could be explained if
Trp167would be properly positioned in the binding crevice of the
3 A. M. Ter Laak and R. Ku¨hne, unpublished observations.
FIG. 5. Zwitterionic H1 antagonists acrivastine (A) and d-cetirizine (B) docked into the H1 receptor model. A, acrivastine, which fits
the cyproheptadine pharmacophore (Fig. 1A), makes an additional (ionic) hydrogen bond interaction with Lys200 (TM V). B, d-cetirizine docked into
the same H1 receptor model and presenting the carboxylate moiety near Lys
200.
TABLE II
Effects of mutation of Lys200 of the histamine H1 receptor on ligand binding and signal transduction
Receptors were expressed in COS-7 cells or HEK-293 cells and used 48 h after transfection for radioligand binding studies and the accumulation
of [3H]inositol phosphates, respectively. The wild type, Lys2003 Ala, Lys2003Met, and Lys2003 Arg were expressed in HEK-293 cells at receptor
densities of respectively 7.1 6 1.0, 13.6 6 1.5, 7.2 6 1.1, and 7.1 6 0.4 pmol/mg protein. Data were calculated as the means 6 S.E. from at least
three independent experiments.
Receptor KD [
3H]mepyramine H1 receptor density Ki histamine EC50 histamine Basal stimulation Ki acrivastine
nM pmol/mg protein mM mM fold nM
wild type 0.7 6 0.1 9.5 6 4.2 76 6 19 0.04 6 0.02 5.9 6 0.4 10 6 3
Lys200 3 Ala 1.6 6 0.2 17.1 6 0.3 320 6 22 2.3 6 1.2 5.3 6 0.5 548 6 52
Lys200 3 Met 1.9 6 0.2 17.3 6 5.1 281 6 18 1.7 6 0.6 5.8 6 0.6 534 6 97
Lys200 3 Arg 5.7 6 0.6 13.9 6 4.7 182 6 5 1.9 6 0.8 7.4 6 0.9 37 6 11
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H1 receptor by an interaction of its indole nitrogen with an-
other (yet unidentified) amino acid of the H1 receptor.
Searching the GRAP mutant data base (31) for mutated
residues at similar positions in other aminergic GPCRs, re-
vealed considerable support for an important role of Trp167,
Phe433, and Phe436 in the binding of the trans-aromatic ring of
the H1 antagonists. A polymorphism of the human b2 receptor
(Thr164 3 Ile) at the position of Trp167 in TM IV has been
reported to alter ligand binding characteristics (32). Moreover,
in the dopamine D2L (33), the 5HT2A (34), and the b2 receptor
(35), a Phe residue in homologous position as Phe433 has been
implicated in hydrophobic or p-p interactions with aromatic
rings of receptor ligands. Similarly, in the muscarinic receptors
an Asn residue is found at the same position as Phe433, and this
Asn507 plays a key role in the binding of various muscarinic
antagonists to the m3 receptor (36). Finally, in both the dopam-
ine D2L (37) and the a1A receptor (38) residues at a homologous
position as Phe436 are also involved in ligand binding.
Because of the perturbed protein expression of the Trp1613
Ala receptor, no conclusive decision could be made regarding its
role in the binding of H1 antagonists. Mutation of Trp
161 with
either Phe or Met is well allowed for high affinity [3H]mepyra-
mine binding or the interaction with histamine. A Trp192 res-
idue at homologous position of Trp161 in the m3 receptor is
important for both agonist and antagonist binding (39), sug-
gesting that Trp161 could be involved in an hydrophobic inter-
action with the cis-ring of the H1 antagonists as well. However,
Trp161 is 96% conserved throughout the GPCR family, suggest-
ing a fundamental role in GPCR architecture (40). We can
therefore not exclude the possibility that a hydrophobic amino
acid at position 161 is simply essential to adopt a functional
GPCR conformation.
Based on the results of the site-directed mutagenesis studies
we concluded that the three-dimensional H1 receptor model
had some predictive value for receptor-ligand interactions. To
challenge our three-dimensional model the zwitterionic ligands
acrivastine and d-cetirizine were fitted into the H1 receptor
model. Both ligands contain a carboxylate moiety in either the
trans-ring (acrivastine) or connected with a spacer to the
amine-function (d-cetirizine). Modeling studies indicated a pos-
sible interaction of the negatively charged group with the
amine of Lys200 in TM V. The Lys2003 Ala H1 receptor mutant
shows normal binding of the classical H1 antagonist [
3H]
mepyramine (10). Our present findings strongly suggest that
Lys200 is directly involved in the binding of the carboxylate
group of acrivastine and d-cetirizine. The Lys200 3 Ala muta-
tion results in a 30- (acrivastine) to 10-fold (d-cetirizine) loss of
affinity of the zwitterionic antagonists, whereas the affinities of
acrivastine and cetirizine analogs lacking the negatively
charged carboxylate group, triprolidine and meclozine, respec-
tively, are not affected by the Lys200 3 Ala mutation. The
Lys200 residue was also mutated to Met, which resembles the
Lys residue sterically but does not contain a protonated amine
function. As predicted, a huge reduction of the affinity of acriv-
astine was observed for the Lys200 3 Met receptor mutant.
Moreover, a basic Arg residue is able to functionally replace
Lys2003 Ala as shown by the high affinity of acrivastine for the
Lys200 3 Arg H1 receptor. These data provide strong evidence
for the hypothesized ionic interaction between the carboxylate
of acrivastine and the protonated amine function of Lys200. As
observed previously for the interaction of histamine with the
Lys2003 Ala mutant receptor (10), histamine was less respon-
sive at the Lys2003Met and Lys2003 Arg H1 receptor as well.
Whereas this is not surprising for the Met mutant (10), the
observations with the Lys200 3 Arg H1 receptor indicate that
the longer arginine side chain and the larger guanidinium
group cannot optimally accommodate the imidazole ring of
histamine. This observation will be important for the refine-
ment of a three-dimensional model for the agonist-binding site.
In view of the emerging cardiotoxicity of several second gen-
eration H1 antagonists (41) and the current interest to combine
potent nonsedative H1 antagonism with other anti-allergic ac-
tivities (3), the identification of the role of Lys200 will be of
importance for the design of potent “third generation” H1 an-
tagonists. The introduction of an carboxylate group in the
structure of the H1 antagonists has by empirical approach been
found to be a very effective way to limit central nervous system
penetration and to derive nonsedative H1 antagonists like ac-
rivastine (42) and cetirizine (43). Consequently, this structural
element can also been found in other new H1 antagonists, e.g.
carebastine, fexofenadine, KF-15766, KW-4679, levocabastine,
and pibaxizine (for review see Ref. 3). Besides leading to favor-
able pharmacokinetics, the carboxylate group also discrimi-
nates the receptor binding of second generation H1 antagonists
acrivastine and cetirizine from the first generation H1 antago-
FIG. 6. Contribution of Lys200 in TM V to the binding of the
zwitterionic H1 antagonists acrivastine and cetirizine and their
structural analogs triprolidine and meclozine to the H1 recep-
tor. A, the binding of [3H]mepyramine to the wild type, Lys200 3 Ala,
Lys2003 Met, and Lys2003 Arg H1 receptor was displaced by acrivas-
tine. The binding of [3H]mepyramine to the wild type and Lys2003 Ala
H1 receptor was displaced by acrivastine and triprolidine (B) and ceti-
rizine and meclozine (C). The data shown are from a representative
example out of at least three independent experiments.
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nists via its interaction with Lys200. Because Lys200 is an
unique residue for the H1 receptor, interaction of ligands with
this residue via a carboxylate group will lead, in addition to
limited brain penetration, probably also to good H1 receptor
selectivity. For future design of nonsedative H1 antagonists the
introduction of a carboxylate group capable of interacting with
Lys200 could therefore be favorable.
In conclusion, our study shows that combining known inter-
acting amino acids of the receptor (Asp116) with a pharmaco-
phore for the H1 antagonist-binding site and verification by
site-directed mutagenesis results in the identification of
Trp167, Phe433, and Phe436 in TM IV and VI as probable inter-
action points for the aromatic rings of H1 antagonists. More-
over, the use of the three-dimensional receptor model allowed
the identification of Lys200 in TM V as specific anchor point for
some nonsedative, zwitterionic H1 antagonists.
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TABLE III
Structural formulas and affinities of the H1 antagonists d-cetirizine, meclozine, acrivastine, and triprolidine for the wild type and Lys
200 3 Ala
H1 receptor
The affinities of the H1 antagonists for the wild type and Lys
200 3 Ala receptor mutant were determined in [3H]mepyramine displacement
studies. Data shown are the means 6 S.E. of at least three independent experiments, each performed in triplicate.
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